← Back to Search

Acetaminophen and Diphenhydramine Only Product for Thrombocytopenic Purpura

Phase 1
Waitlist Available
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if it's possible to enroll children with ITP who are receiving IVIG for treatment, and if they're willing to participate in a scheduled medication regimen. They will also test if patients and families are able to stick to the schedule.

Eligible Conditions
  • Idiopathic Thrombocytopenic Purpura (ITP)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Eligible Patients Agreeing to Enrollment
Secondary study objectives
Percentage of Enrolled Patients who Achieve Medication Adherence
Rate of Laboratory Evaluation with Platelet Count During Emergent Medical Evaluation
Cognitive Therapy
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Scheduled post-IVIG medicationExperimental Treatment1 Intervention
Utilization of post-IVIG medication with acetaminophen and diphenhydramine on a scheduled basis of 72 hours post-infusion.

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
1,022 Previous Clinical Trials
6,029,400 Total Patients Enrolled

Media Library

Acetaminophen and Diphenhydramine Only Product Clinical Trial Eligibility Overview. Trial Name: NCT04741139 — Phase 1
Thrombocytopenic Purpura Research Study Groups: Scheduled post-IVIG medication
Thrombocytopenic Purpura Clinical Trial 2023: Acetaminophen and Diphenhydramine Only Product Highlights & Side Effects. Trial Name: NCT04741139 — Phase 1
Acetaminophen and Diphenhydramine Only Product 2023 Treatment Timeline for Medical Study. Trial Name: NCT04741139 — Phase 1
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top